Study drug for TP53 Y220C-mutated advanced cancers
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old (or 12–17 after safety review).
- Your cancer is solid tumor that is advanced or has spread, and has the TP53 Y220C mutation.
- You have had at least one prior cancer treatment, and the cancer is still growing.
- Your body function tests are adequate (organ function and blood counts).
- Your performance status is 0 or 1 (you can do daily activities with little or some help).
- Your cancer can be measured on scans (measurable disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (called LG00313112) for people with advanced solid tumors that have a specific genetic change called TP53 Y220C. The drug aims to target this change and may help slow or stop cancer growth.
This trial tests a personalized cell therapy called TP53 R248Q TCR-T for people with advanced solid tumors that have a specific genetic change (TP53 R248Q mutation). The treatment uses your own immune cells modified to attack cancer cells, and may be an option if standard treatments are no longer working.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
This trial tests a new drug called YL242 in people with advanced solid tumors that have not responded to prior treatment or have not been treated yet. It looks at safety, how well the drug works, and includes different groups based on cancer type and prior therapy.
This early-stage study tests a new drug (HEC169096) in people with advanced solid tumors that cannot be removed by surgery. It focuses on tumors with specific RET gene changes, aiming to control or shrink the cancer and improve outcomes.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.